Anlotinib plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: A prospective, single-arm, single-center, phase II clinical study

被引：1
|
作者：
Chen, X. [1 ]
Zhang, S. [1 ]
Li, X. [2 ]
Zhang, Y. [1 ]
Li, Y. [2 ]
Kang, H. [1 ]
Guan, H. [1 ]
She, Q. [2 ]
Ma, X. B. [1 ]
Diao, Y. [1 ]
Liu, D. [1 ]
Min, W. [1 ]
Liu, M. [1 ]
Wu, F. [1 ]
Feng, C. [1 ]
机构：
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Oncol, Xian, Peoples R China
[2] Baoji Cent Hosp, Oncol, Baoji, Shaanxi, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.450
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
169P
引用
收藏
页码：S433 / S433
页数：1
相关论文
共 50 条
  • [1] Anlotinib plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: A prospective, single-arm, single-center, phase II clinical study.
    Chen, Xi
    Zhang, Shuqun
    Li, Xuexin
    Zhang, Yinbin
    Li, Youhuai
    Kang, Huafeng
    Guan Haitao
    She, Qing
    Ma, Xiaobin
    Diao, Yan
    Liu, Di
    Min, Weili
    Liu, Mengjie
    Wu, Fei
    Feng, Cong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial
    Yang, Ciqiu
    Zhang, Junsheng
    Zhang, Yi
    Ji, Fei
    Chen, Yitian
    Zhu, Teng
    Zhang, Liulu
    Gao, Hongfei
    Yang, Mei
    Li, Jieqing
    Cheng, Minyi
    Wang, Kun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [3] Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): A single-center, single-arm, phase II trial.
    Yang, Ciqiu
    Zhang, Junsheng
    Wang, Kun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study.
    Luo, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
    Huang, Jia-Yi
    Xie, Xiao-Feng
    Chen, Xue-Lian
    Zhang, Qiu-Yi
    Chen, Li-Ping
    Bai, Xue
    Lan, Xiao-Feng
    Song, Lin
    Guo, Jin-Feng
    Du, Cai-Wen
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: a experimental single-arm phase II clinical trial pilot study
    Zheng, Chunhui
    Liu, Yanbing
    Wang, Xue'er
    Bi, Zhao
    Qiu, Pengfei
    Qiao, Guangdong
    Bi, Xiang
    Shi, Zhiqiang
    Zhang, Zhaopeng
    Chen, Peng
    Sun, Xiao
    Wang, Chunjian
    Zhu, Shiguang
    Meng, Xiangjing
    Song, Yunjie
    Qi, Yingxue
    Li, Lu
    Luo, Ningning
    Wang, Yongsheng
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (03) : 1527 - 1536
  • [7] Neoadjuvant anlotinib plus nab-paclitaxel based chemotherapy in patients with HER2-negative breast cancer: A prospective, single-arm, single-center, phase II clinical study
    Fan, Jing
    Wang, Ting
    Meng, Huimin
    Li, Songpeng
    Kong, Jing
    Wang, Yidi
    CANCER RESEARCH, 2023, 83 (05)
  • [8] A commentary on 'Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: an experimental single-arm phase II clinical trial pilot study'
    Zhang, Lei
    Ma, Guannan
    Jiang, Yanfang
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (06) : 3964 - 3965
  • [9] Anlotinib plus chemotherapy as first-line treatment for advanced ovarian cancer: a prospective, single-arm, single-center, phase II clinical study
    Liu, Dechun
    Yan, Tao
    Zhang, Qian
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S89 - S90
  • [10] A prospective single-center, single-arm, open-label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer
    Duan, Hongtao
    Wang, Zhaoyang
    Cao, Lili
    Zhu, Yifang
    Tong, Liping
    Yan, Xiaolong
    THORACIC CANCER, 2024, 15 (19) : 1471 - 1476
12345